What is BioSkryb?
BioSkryb Genomics operates at the intersection of biotechnology and high-throughput sequencing, specializing in the development of advanced genomic amplification technologies. The company's core innovation, the Primary Template-directed Amplification (PTA) system, represents a significant leap forward in the ability to generate high-quality sequencing libraries from limiting or ultra-low input samples. By delivering superior coverage breadth and uniformity, BioSkryb enables researchers and clinicians to extract actionable insights from genetic material that was previously considered too degraded or scarce for reliable analysis. This technological edge provides the company with a distinct competitive advantage in the global genomics market, where the demand for high-fidelity data remains a primary driver for both academic research and clinical diagnostic development.
How much funding has BioSkryb raised?
BioSkryb has raised a total of $11.5M across 1 funding round:
Angel/Seed
$11.5M
Angel/Seed (2020): $11.5M with participation from Anzu Partners and Wilson Sonsini Goodrich & Rosati
Key Investors in BioSkryb
Anzu Partners
Anzu Partners is an investment firm focused on breakthrough technologies in clean tech, industrial, and life sciences sectors, managing $1 billion in assets.
Wilson Sonsini Goodrich & Rosati
Wilson Sonsini Goodrich & Rosati is a premier law firm providing comprehensive legal services to technology, life sciences, and growth enterprises.
What's next for BioSkryb?
With the recent strategic investment, BioSkryb is well-positioned to scale its operations and accelerate the commercialization of its PTA-based solutions. The company is expected to focus on expanding its footprint within the life sciences ecosystem, potentially targeting broader adoption in clinical diagnostics and large-scale population genomics projects. As the firm transitions from its initial development phase toward broader market penetration, the focus will likely shift toward optimizing manufacturing processes and forging strategic partnerships with major sequencing platform providers. By leveraging its current financial runway, BioSkryb aims to solidify its status as a standard-bearer for high-quality genetic analysis, ensuring that its proprietary technology becomes an indispensable tool for the next generation of genomic discovery.
See full BioSkryb company page
